- Home
- SOL vs ICCM Comparison
SOL vs ICCM Comparison
Compare SOL & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- ICCM
- Stock Information
- Founded
- SOL 2005
- ICCM 2006
- Country
- SOL United States
- ICCM Israel
- Employees
- SOL N/A
- ICCM N/A
- Industry
- SOL Semiconductors
- ICCM
- Sector
- SOL Technology
- ICCM
- Exchange
- SOL Nasdaq
- ICCM Nasdaq
- Market Cap
- SOL 84.6M
- ICCM 70.1M
- IPO Year
- SOL 2008
- ICCM N/A
- Fundamental
- Price
- SOL $1.48
- ICCM $1.03
- Analyst Decision
- SOL Buy
- ICCM Strong Buy
- Analyst Count
- SOL 3
- ICCM 1
- Target Price
- SOL $3.50
- ICCM $2.50
- AVG Volume (30 Days)
- SOL 162.2K
- ICCM 199.2K
- Earning Date
- SOL 05-22-2025
- ICCM 05-27-2025
- Dividend Yield
- SOL N/A
- ICCM N/A
- EPS Growth
- SOL N/A
- ICCM N/A
- EPS
- SOL N/A
- ICCM N/A
- Revenue
- SOL $92,067,000.00
- ICCM $3,291,000.00
- Revenue This Year
- SOL N/A
- ICCM $97.02
- Revenue Next Year
- SOL $45.37
- ICCM $212.86
- P/E Ratio
- SOL N/A
- ICCM N/A
- Revenue Growth
- SOL N/A
- ICCM 1.92
- 52 Week Low
- SOL $1.04
- ICCM $0.48
- 52 Week High
- SOL $3.00
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- SOL 56.58
- ICCM 37.29
- Support Level
- SOL $1.25
- ICCM $1.00
- Resistance Level
- SOL $1.40
- ICCM $1.10
- Average True Range (ATR)
- SOL 0.07
- ICCM 0.08
- MACD
- SOL 0.03
- ICCM -0.01
- Stochastic Oscillator
- SOL 79.39
- ICCM 8.82
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.